Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
Loke, Justin Upasani, Vinit Gaskell, Charlotte Fox, Sonia Fletcher, Rachel Thomas, Catherine Hopkins, Louise Kumari, Anita Tang, Tina Yafai, Emily
Loke, Justin
Upasani, Vinit
Gaskell, Charlotte
Fox, Sonia
Fletcher, Rachel
Thomas, Catherine
Hopkins, Louise
Kumari, Anita
Tang, Tina
Yafai, Emily
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2023-06-12
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Limited data exist on COVID-19 vaccination efficacy in patients with acute myeloid leukemia and myelodysplasia with excess blasts (AML/MDS-EB2). We report results from a prospective study, PACE (Patients with AML and COVID-19 Epidemiology). 93 patients provided samples post-vaccine 2 or 3 (PV2, PV3). Antibodies against SARS-COV-2 spike antigen were detectable in all samples. Neutralization of the omicron variant was poorer than ancestral variants but improved PV3. In contrast, adequate T-cell reactivity to SARS-COV-2 spike protein was seen in only 16/47 (34%) patients PV2 and 23/52 (44%) PV3. Using regression models, disease response (not in CR/Cri), and increasing age predicted poor T cell response.
Citation
Br J Haematol . 2023 Aug;202(3):498-503
Type
Article